Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
STRO-001 Recombinant Human Monoclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MA562747
应用
建议稀释比
已发表文章
产品规格
种属反应
Human
宿主/亚型
Human
/ IgG1
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
偶联物
形式
Liquid
浓度
1 mg/mL
纯化类型
Protein A/G
保存液
PBS, pH 7.4
内含物
no preservative
保存条件
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
STRO-001 is an investigational antibody-drug conjugate (ADC) developed by Sutro Biopharma targeting CD74 a cell surface receptor implicated in the survival and proliferation of various hematologic malignancies including multiple myeloma and non-Hodgkin lymphoma. This ADC utilizes Sutro's proprietary XpressCF+ technology allowing precise conjugation of the cytotoxic payload tubulin inhibitor maytansine to the CD74-targeted monoclonal antibody. STRO-001 aims to bind specifically to CD74-expressing cells facilitating direct delivery of the cytotoxic agent to tumor cells thus minimizing impact on healthy tissue. Clinical studies investigate the safety tolerability and therapeutic effects of STRO-001 in patients focusing on optimizing dosing and evaluating antitumor activity. Preclinical results have demonstrated significant antitumor efficacy in xenograft models highlighting its potential role in targeted cancer therapy particularly in hematologic malignancies where CD74 is highly expressed.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
